Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022

Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility

Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business

Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum

Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2022 and Recent Developments

Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022

Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility

Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2022 After Market Close on December 7, 2021

Avid Bioservices Appoints Elie G. Hanania, Ph.D., as Vice President, Process Development, Viral Vector Technologies